Dear colleagues and friends,
We would like to invite you to a seminar by
Leyuan Ma (Perelman School of Medicine, University of Pennsylvania)
Vaccine stimulation of bystander T cells in the lymph node unexpectedly promotes tumor-specific host immunity to regress pancreatic cancer
Friday, 20.03.2026 | 15:00 TranslaTUM Small Auditorium, Einsteinstraße 25, 81675 München
Leyuan is an Assistant Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. He earned his B.S. in Biosciences and Bioengineering from Shandong Normal University in 2008 and his Ph.D. in Molecular, Cell and Cancer Biology from the University of Massachusetts Medical School in 2016. He then completed postdoctoral training in immunotherapy and immune engineering at MIT and HHMI in the lab of Darrell Irvine, where he worked on synthetic booster vaccines to enhance CAR T-cell therapy for solid tumors. Leyuan joined Penn in 2022 and is also affiliated with the Raymond G. Perelman Center for Cellular and Molecular Therapeutics at CHOP.
His research sits at the interface of immunology and engineering and focuses on understanding how immune cells communicate with each other and with their surrounding tissues in health and disease. His group uses genetic, chemical, engineering, computational, and mouse-model approaches to decode this immune crosstalk and translate it into new precision immunotherapies. The lab’s main translational areas include biomaterials, therapeutic proteins, vaccines, and engineered cell therapies for cancer, autoimmune disease, solid tumors, and transplantation tolerance. Highlighted projects include synthetic booster vaccines for CAR T-cell therapy, matrix-anchored cytokine therapeutics, and CRISPR-based approaches to better predict clinical drug resistance.
If you would like to meet Leyuan, please contact Dieter (dieter.saur@tum.de).
We are looking forward to welcome you to the talk!
Best wishes,
Dieter
Host: Dieter Saur
Division of Translational Cancer Research, German Cancer Research Center, Heidelberg; Institute of Experimental Cancer Therapy, DKTK partner site Munich and TranslaTUM – Central Institute for Translational Cancer Research, School of Medicine and Health, Technical University of Munich
